<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00066599</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000316329</org_study_id>
    <secondary_id>NCI-03-C-0218</secondary_id>
    <nct_id>NCT00066599</nct_id>
    <nct_alias>NCT00062920</nct_alias>
  </id_info>
  <brief_title>Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy</brief_title>
  <official_title>An Open-Label, Intravenous To Oral Switch, Multiple Dose, Multi-Center Study To Investigate The Pharmacokinetics, Safety And Tolerability Of Voriconazole In Hospitalized Children Aged 2 - &lt;12 Years Who Require Treatment For The Prevention Of Systemic Fungal Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Voriconazole may be effective in preventing systemic fungal infections following&#xD;
      chemotherapy.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of voriconazole in preventing systemic&#xD;
      fungal infections in children who have neutropenia after receiving chemotherapy for leukemia,&#xD;
      lymphoma, or aplastic anemia or in preparation for bone marrow or stem cell transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the pharmacokinetics of voriconazole administered IV and orally for the&#xD;
           prevention of systemic fungal infection in pediatric patients with neutropenia after&#xD;
           chemotherapy.&#xD;
&#xD;
        -  Determine the safety and tolerability of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a pilot, open-label, multicenter study. Patients are stratified according to&#xD;
      age (2 to 5 vs 6 to 11).&#xD;
&#xD;
      Within 48 hours after completion of chemotherapy, patients begin prophylactic therapy:&#xD;
&#xD;
        -  Cohort 1 (the first 18 patients, 9 per stratum): Patients receive voriconazole IV over&#xD;
           80-160 minutes twice daily on days 1-8 and oral voriconazole* twice daily beginning on&#xD;
           day 9.&#xD;
&#xD;
      Depending on the results of the interim pharmacokinetic analysis, the last 18 patients&#xD;
      entered on the study receive 1 of the following regimens:&#xD;
&#xD;
        -  Cohort 2A:Patients receive voriconazole as in cohort 1 at a higher dose.&#xD;
&#xD;
        -  Cohort 2B: Patients receive voriconazole IV over 80-160 minutes twice daily on days 1-4&#xD;
           and oral voriconazole* twice daily beginning on day 5.&#xD;
&#xD;
      NOTE: *Patients who are unable to tolerate oral medication may continue receiving IV&#xD;
      medication until day 20.&#xD;
&#xD;
      In all cohorts, treatment continues until blood counts recover or day 30 in the absence of&#xD;
      unacceptable toxicity or progression of infection.&#xD;
&#xD;
      Patients are followed at 30 days and at 12 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 49 patients (approximately 24 per stratum) were accrued for&#xD;
      this study within 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">June 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Kidney Cancer</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasms</condition>
  <condition>Neuroblastoma</condition>
  <condition>Neutropenia</condition>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>voriconazole</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Expected to develop neutropenia (absolute neutrophil count less than 500/mm^3) lasting&#xD;
             for more than 10 days after chemotherapy for 1 of the following conditions:&#xD;
&#xD;
               -  Leukemia&#xD;
&#xD;
               -  Lymphoma&#xD;
&#xD;
               -  Aplastic anemia&#xD;
&#xD;
               -  Preparation for a bone marrow or stem cell transplantation&#xD;
&#xD;
          -  Requiring treatment for the prevention of systemic fungal infection&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  2 to 11&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT no greater than 5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin no greater than 5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance at least 30 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  No severe hypokalemia (potassium less than 3.2 mmol/L)&#xD;
&#xD;
          -  No prior hypersensitivity to or severe intolerance of azole antifungal agents&#xD;
&#xD;
          -  No other concurrent condition that would preclude study therapy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 24 hours since prior use of any of the following:&#xD;
&#xD;
               -  Terfenadine&#xD;
&#xD;
               -  Pimozide&#xD;
&#xD;
               -  Quinidine&#xD;
&#xD;
               -  Astemizole&#xD;
&#xD;
               -  Cisapride&#xD;
&#xD;
               -  Omeprazole&#xD;
&#xD;
          -  More than 14 days since prior use of any of the following:&#xD;
&#xD;
               -  Rifampin&#xD;
&#xD;
               -  Rifabutin&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Nevirapine&#xD;
&#xD;
               -  Long-acting barbiturates&#xD;
&#xD;
          -  No prior sirolimus&#xD;
&#xD;
          -  No prior enrollment on this study&#xD;
&#xD;
          -  No concurrent use of any of the following:&#xD;
&#xD;
               -  Terfenadine&#xD;
&#xD;
               -  Pimozide&#xD;
&#xD;
               -  Quinidine&#xD;
&#xD;
               -  Astemizole&#xD;
&#xD;
               -  Cisapride&#xD;
&#xD;
               -  Omeprazole&#xD;
&#xD;
          -  No other concurrent investigational drugs except any of the following:&#xD;
&#xD;
               -  Drugs used as treatment for cancer&#xD;
&#xD;
               -  Antiretroviral agents&#xD;
&#xD;
               -  Drugs used for the treatment of any AIDS-defining opportunistic infections&#xD;
&#xD;
          -  No concurrent enrollment in investigational anticancer drug trials that exclude the&#xD;
             use of other investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas J. Walsh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Health Center, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123-4282</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ireland Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simmons Cancer Center at University of Texas Southwestern Medical Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2004</verification_date>
  <study_first_submitted>August 6, 2003</study_first_submitted>
  <study_first_submitted_qc>August 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2003</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2013</last_update_posted>
  <keyword>neutropenia</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>stage I childhood lymphoblastic lymphoma</keyword>
  <keyword>stage II childhood lymphoblastic lymphoma</keyword>
  <keyword>stage III childhood lymphoblastic lymphoma</keyword>
  <keyword>stage IV childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage I childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage II childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage III childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>stage I childhood large cell lymphoma</keyword>
  <keyword>stage II childhood large cell lymphoma</keyword>
  <keyword>stage III childhood large cell lymphoma</keyword>
  <keyword>stage IV childhood large cell lymphoma</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>untreated childhood acute myeloid leukemia and other myeloid malignancies</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>stage I childhood Hodgkin lymphoma</keyword>
  <keyword>stage II childhood Hodgkin lymphoma</keyword>
  <keyword>stage III childhood Hodgkin lymphoma</keyword>
  <keyword>stage IV childhood Hodgkin lymphoma</keyword>
  <keyword>childhood acute promyelocytic leukemia (M3)</keyword>
  <keyword>previously treated childhood rhabdomyosarcoma</keyword>
  <keyword>recurrent Wilms tumor and other childhood kidney tumors</keyword>
  <keyword>recurrent childhood rhabdomyosarcoma</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>meningeal chronic myelogenous leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>intraocular lymphoma</keyword>
  <keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>acute undifferentiated leukemia</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>untreated childhood acute lymphoblastic leukemia</keyword>
  <keyword>disseminated neuroblastoma</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent neuroblastoma</keyword>
  <keyword>atypical chronic myeloid leukemia, BCR-ABL1 negative</keyword>
  <keyword>myelodysplastic/myeloproliferative neoplasm, unclassifiable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Voriconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

